GlaxoSmithKline News and Research

RSS

Cervarix shows long-term protection from cervical cancer

New data demonstrate that GlaxoSmithKline's cervical cancer candidate vaccine, CERVARIX provides significant protection for women against the four most common cancer- causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to date.

12 Mar 2008

New global study of targeted therapies for breast cancer

Two targeted medications designed to treat an aggressive form of breast cancer are being tested in a new study involving 8,000 participants in 50 countries across six continents -- a clinical trial that investigators hope will provide a new model for global cancer research.

1 Mar 2008

Barr confirms Avodart patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by GlaxoSmithKline in connection with its Avodart(R) (dutasteride) soft gelatin capsules, 0.5mg.

27 Feb 2008

SSRI anti-depressants found to offer little clinical benefit

According to new research from Britain, new generation anti-depressants could be for many patients a waste of time and money and offer little clinical benefit.

26 Feb 2008

US advisory committee recommends approval of Rotarix

The US Advisory Committee on Vaccines and Related Biological Products issued a positive recommendation today on the use of rotavirus vaccines, potentially bringing greater protection to children in the US from this common and sometimes fatal cause of severe diarrhea.

21 Feb 2008

Vaccinex antibody licensed to GlaxoSmithKline

EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

18 Feb 2008

Scientists reveal a new target to fight bad cholesterol

Scientists have uncovered a new region in the genome that is responsible for the body's ability to regulate bad cholesterol which is linked to heart attack and stroke.

8 Feb 2008

For safety, NHLBI changes intensive blood sugar treatment strategy in trial of diabetes and cardiovascular disease

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped one treatment within a large, ongoing North American clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns after review of available data, although the study will continue.

6 Feb 2008

Australian gene test opens door to personalised care

Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.

6 Feb 2008

European regulatory agencies should employ full-time statisticians

European regulatory agencies should employ full time statisticians to enable competent licensing and labelling decisions to be made, argue leading statisticians in an open letter to this week's BMJ.

5 Feb 2008

Resisting lung cancer recurrence - Vaccine booster gives persistent immune response

What if we could prevent cancer recurrence for years after surgery by giving simple recall injections every two or three years? This concept may no longer be a fantasy.

4 Feb 2008

Scientists recreate rhinovirus infection in mice - hope of new asthma treatments

Scientists have been able to recreate rhinovirus infection, which is behind most common colds, in a small animal for the first time.

4 Feb 2008

Medical Research Council and GSK to identify new therapeutic targets from genetic association studies

The Medical Research Council (MRC) and GlaxoSmithKline (GSK) have announced the creation of a jointly funded programme seeking to identify and validate genes associated with common human diseases. A key aim of the programme will be to translate these observations into new drug targets and biomarkers of disease.

28 Jan 2008

Ranbaxy settles with GlaxoSmithKline on Imitrex

Ranbaxy Laboratories Limited (Ranbaxy) has announced that it has settled all matters relating to possible patent litigation with GlaxoSmithKline relating to Sumatriptan Succinate Tablets, the generic version of GlaxoSmithKline's Imitrex Tablets.

22 Jan 2008

Genmab reaches milestones in Ofatumumab collaboration

The second milestone payment of the collaboration of DKK 87.2 million was triggered by treatment of the first patient in the Phase II study of ofatumumab in Diffuse Large B-Cell Lymphoma (DLBCL), which occurred in 2007.

22 Jan 2008

Selective publication means unfavorable drug studies rarely get published

A new report claims that almost a third of the research done on antidepressant drugs is never published in medical literature and most of those unpublished reports are unfavorable.

20 Jan 2008

Drug effective for hepatitis C patients with low platelets

For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease.

2 Jan 2008

Combo therapy reduces size of brain tumours

According to a major drug manufacturer, a combination drug treatment appears to be effective in fighting breast cancer that has spread to the brain.

19 Dec 2007

Targeted therapy and chemotherapy shrinks breast cancer metastases in brain

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

17 Dec 2007

GlaxoSmithKline response to JAMA article on ICES retrospective analysis

The following is GlaxoSmithKline's response to the retrospective analysis by the Institute for Clinical Evaluative Sciences (ICES) titled "Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes".

13 Dec 2007